United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Comerica

Chevron

Dow Inc

Altria

Verizon

24/7 Wall St. Insights Blue chip dividend stocks are among the safest equities investors can own.

6 Blue-Chip Dividend Giants Every Passive Income Investor Should Own

Moderna

US regulators have approved a new series of updated and improved COVID-19 vaccines to target a resurgence of the virus as new strains emerge. Pfizer Inc (NYSE:PFE, ETR:PFE) and Moderna Inc (NASDAQ:MRNA, ETR:0QF) are set to begin shipping immediately while a third US manufacturer, Novavax, expects to start deliveries later.

New Pfizer and Moderna Covid-19 vaccines approved by US

The Food and Drug Administration on Thursday gave Pfizer Inc. and Moderna Inc. approval for updated COVID-19 vaccines, as a summer wave of the virus is still rolling across the country.

Updated COVID-19 vaccines from Pfizer, Moderna approved by FDA

BioNTech SE

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies' Omicron KP.2-adapted 2024-202.

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

The Food and Drug Administration approved updated Covid vaccines from Pfizer and Moderna, putting the shots on track to reach most Americans in the coming days as the virus surges. The jabs target a strain called KP.2, a descendant of the highly contagious omicron subvariant JN.1 that began circulating widely in the U.S. earlier this year.

FDA approves updated Pfizer, Moderna Covid vaccines as virus surges; shots to be available within days

Ford Motor Company

Dividend stocks are a valuable addition to any investment portfolio, offering a reliable income stream that can provide stability in both bullish and bearish markets. High dividend yields are particularly attractive, especially when paired with fundamentally sound and potentially undervalued stocks.

These 3 Stocks Pay You More Than 5% to Own Them

Apple

Ares Capital

Bank of America

BHP Billiton

Blackrock Inc

British American Tobacco

Alphabet

iShares Core High Dividend ETF

Johnson & Johnson

JPMorgan Chase & Co

Coca-Cola

Mastercard

Main Street Capital

Microsoft

NIKE

Realty Income Corp

PepsiCo

Philip Morris

Cohen & Steers Quality Income Realty Fund

Royal Bank of Canada

Schwab US Dividend Equity ETF

AT&T

TCP Capital

I will demonstrate how you could allocate the amount of $100,000 by following the current composition of The Dividend Income Accelerator Portfolio, effectively balancing dividend income and dividend growth. Potential benefits of its implementation are a reduced portfolio risk level, stable dividend income, strong potential for dividend growth and capital appreciation, and elevated chances of an attractive Total Return. The dividend portfolio presently offers you a Weighted Average Dividend Yield [FWD] of 4.20%, with a 5-Year Weighted Average Dividend Growth Rate [CAGR] of 7.31%.

How To Allocate $100,000 In A Dividend Portfolio: A Strategic Guide For Income And Growth

24/7 Wall St. Insights Pfizer is one of the highest-yielding S&P 500 stocks.

Looking for $1500 in Safe Passive Income Each Year? Invest This Much in Pfizer.

Pfizer stock slipped close to a sell zone after its Covid/flu vaccine missed the mark in final-phase testing. Is PFE stock a buy or a sell?

Is Pfizer Stock A Buy Or A Sell After Covid/Flu Shot Misses Its Mark?

AGNC Investment

Eagle Point Credit

Ellington Financial

Estee Lauder

Euroseas

Energy Transfer LP Unit

FS KKR Capital Corp

Noah Holdings Ltd.

Oxford Lane Capital

Petroleo Brasileiro

PIMCO Dynamic Income Fund

Provident Financial Services

Vale S.A.

Invesco Senior Income Trust

XAI Octagon Floating Rate & Alternative Income Term Trust

Before July 31, 2024, my REaders mentioned 38 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers commented about the ReFa/Ro. Ten analyst-target-estimated TOP-NET-GAIN ReFa/Ro: FSK, PFE, VZ, PFS, PBR, ET, ESEA, EL, VALE, and NOAH averaged 41.06% net gains from reader data collected 8/14/24. Ten analyst-target-augured July TOP-PRICE-UPSIDE reader faves & rogues (ReFa/Ro) were: XOM, PBR, PFE, VZ, PFS, ET, ESEA, EL, VALE & NOAH, boasting a 33.38% average target price upside estimate.

Readers Identify 25 Ideal July Dividend Buys Out Of 37 Picks

After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.

How Should You Play Pfizer (PFE) After COVID-Flu Shot Setback?

Toyota Motor

Social Security faces potential benefit reductions after 2035. Dividend-paying stocks can form a solid basis for a passive income portfolio.

2 Cheap Passive Income Stocks to Buy Now

AstraZeneca

GlaxoSmithKline

Eli Lilly

Merck

Novo Nordisk

Novartis

In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.

Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings

News for Pfizer Stock (PFE)